Summary

The gene editing market is expected to reach USD 7.59 billion in 2029 from USD 4.66 billion in 2024, at a CAGR of 10.2% during the forecast period.
Factors such as advancements in gene editing technologies, and the expanding range of gene editing applications are driving the growth of the gene editing market. However, the market faces several challenges due to off-target effects of gene editing, along with difficulties in scalability and manufacturing, pose significant hurdles.
“The product segment accounted for the largest share by offerings segment in the gene editing market in 2023”
By offerings, the gene editing market is segmented into products and services. The products segment held the largest share in 2023. The demand for products in gene editing process including experimentation and research for cell line development and drug development & discovery make them an indispensable part of the gene market. Gene editing products as reagents & consumables and Software & systems like gene editing kits, gene editing reagents and gene editing libraries are utilized by pharmaceutican & biotechnology companies and academic & research institutes in various gene editing workflow. Services held the second highest share of the gene editing market in 2023.
“The CRISPR technology held the highest market share of the gene editing products market by technology in 2023”
By Technology, the gene editing products market is segmented into CRISPR, TALEN, ZFN, Base editing, Antisense, RNAi and other technologies which include piggybac and prime editing among others. The CRISPR segment held the highest share of the gene editing products by technology market in 2023 driven by advancements in CRISPR technology leading to large scale adoption of this technology in gene editing. Gene editing products are used in a large range of CRISPR applications including reagents like Cas-9, vectors, libraries for screening and target identification and CRISPR based gene editing kits. Still, TALEN segment held the second largest share of the market in 2023.
“The Asia Pacific region is growing at the highest CAGR in the gene editing market from 2024 to 2029.”
The Asia Pacific is estimated to be the fastest-growing segment of the market owing to the a significant focus on R&D activities, funding by government and private players in gene editing research, and rising adoption of gene editing technologies in drug discovery & development. Further, the rising prevalence of rare and genetic diseases is attributed to the aging population of countries such as Japan, and China. This is supporting the adoption of gene editing technologies in healthcare management and treatment driving the market growth. However, North America held the largest share of gene editing market in 2023.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 70% and Demand Side 30%
• By Designation: Managers - 45% CXOs and Director-level - 30%, and Executives - 25%,
• By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5%, and Middle East -5%.

List of Companies Profiled in the Report:
• Thermo fisher scientific Inc. (US)
• Merck KGaA (Germany)
• GenScript (US)
• Agilent Technologies, Inc. (US)
• Revvity (US)
• Lonza (US)
• Tecan Trading AG (Switzerland)
• Sangamo therapeutics (US)
• Precision BioSciences (US)
• Cellectis S.A. (France)
• Regeneron Pharmaceuticals Inc. (US)
• AMSBIO (UK)
• Creative Biogene (US)
• Synthego (US)
• Takara Bio Inc. (Japan)
• Bio-Techne (US)
• Caribou Biosciences, Inc. (US)
• Bioneer corporation (South Korea)
• REPROCELL Inc. (Japan)

Research Coverage:
This research report categorizes the gene editing market by offerings (products and services), products by type (reagnets & consumables, and software & systems), reagents & consumables by Technique (knock-out, knock-in, gene silencing, and other techniques), products by technology (CRISPR, TALEN, ZFN, Base editing, Antisense, RNAi and other technologies), products by application (cell line engineering, genome editing/genetic engineering, drug discovery & development, and other applications), products by end user (pharmaceutical & biotechnology companies, academic & research institutes, CROs & CDMOs, and other end users), services by type (cell line engineering, gRNA synthesis & vector construction, library construction & screening, and other types), services by application (cell line development & engineering, genome editing/genetic engineering, drug discovery & development, and other applications), services by end user (pharmaceutical & biotechnology companies, academic & research institutes, and other end users) and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints influencing the growth of the genomics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, product & service portfolio, key strategies such as product & service launches, collaborations, partnerships, expansions, agreements, and recent developments associated with the gene editing market. Competitive analysis of top players and upcoming startups in the gene editing market ecosystem is covered in this report.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall gene editing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
Analysis of key drivers (Increasing demand for personalized medicine, Favorable government funding investments for gene editing projects, Expanding applications of gene editing), restraints (Off-Target Effects and Safety Concerns), opportunities (Technological advancements in Prime editing and bridge RNA, Rising burden of congenital disorders), and challenges (Issues with scalability of gene editing workflows. High equipment and facility costs) influencing the growth of the market.
• Product Development/Innovation: Detailed insights on newly launched product/services of the gene editing market
• Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the gene editing market
• Competitive Assessment: Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), GenScript (US), Agilent Technologies, Inc. (US), Revvity (US), Lonza (US), Tecan Trading AG (Switzerland), Sangamo therapeutics (US). Precision BioSciences (US), Cellectis S.A. (France), Regeneron Pharmaceuticals Inc. (US), AMSBIO (UK), Creative Biogene (US), Synthego (US), Takara Bio Inc. (Japan), Bio-Techne (US), Caribou Biosciences, Inc. (US) Bioneer corporation (South Korea), and REPROCELL Inc. (Japan).

ページTOPに戻る

Table of Contents

1 INTRODUCTION 43
1.1 STUDY OBJECTIVES 43
1.2 MARKET DEFINITION 43
1.3 STUDY SCOPE 44
1.3.1 MARKETS COVERED 44
1.3.2 INCLUSIONS & EXCLUSIONS 45
1.3.3 YEARS CONSIDERED 46
1.3.4 CURRENCY CONSIDERED 46
1.4 LIMITATIONS 46
1.5 STAKEHOLDERS 46
1.6 SUMMARY OF CHANGES 47
2 RESEARCH METHODOLOGY 48
2.1 RESEARCH DATA 48
2.1.1 SECONDARY DATA 49
2.1.2 PRIMARY DATA 50
2.2 MARKET ESTIMATION METHODOLOGY 51
2.2.1 MARKET ESTIMATION 51
2.2.1.1 Insights of primary experts 53
2.2.2 SEGMENTAL MARKET SIZE ESTIMATIONS 54
2.3 MARKET GROWTH RATE PROJECTIONS 55
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 57
2.5 RESEARCH ASSUMPTIONS 58
2.6 RESEARCH LIMITATIONS 58
2.7 RISK ANALYSIS 59
3 EXECUTIVE SUMMARY 60
4 PREMIUM INSIGHTS 66
4.1 GENE EDITING MARKET OVERVIEW 66
4.2 NORTH AMERICA: GENE EDITING MARKET, BY TYPE AND COUNTRY (2023) 67
4.3 GENE EDITING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 67
5 MARKET OVERVIEW 68
5.1 INTRODUCTION 68
5.2 MARKET DYNAMICS 68
5.2.1 DRIVERS 69
5.2.1.1 Increasing demand for personalized medicine 69
5.2.1.2 Favorable government funding investments for gene editing projects 71
5.2.1.3 Expanding applications of gene editing 72
5.2.2 RESTRAINTS 72
5.2.2.1 Off-target effects and safety concerns 72
5.2.3 OPPORTUNITIES 73
5.2.3.1 Rising technological advancements in prime editing and bridge RNA 73
5.2.3.2 Increasing burden of congenital disorders 73
5.2.4 CHALLENGES 74
5.2.4.1 Issues associated with scalability of gene editing workflows 74
5.2.4.2 High equipment & manufacturing costs 74
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 75
5.4 PRICING ANALYSIS 76
5.4.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY CONSUMABLE (2023) 76
5.4.2 AVERAGE COST RANGE OF GENE EDITING KITS & REAGENTS, 2021−2023 77
5.4.3 AVERAGE SELLING PRICE TREND OF SERVICES, BY TYPE 78
5.4.4 AVERAGE SELLING PRICE, BY REGION 79
5.5 SUPPLY CHAIN ANALYSIS 81
5.6 VALUE CHAIN ANALYSIS 82
5.7 ECOSYSTEM ANALYSIS 86
5.8 IMPACT OF GENERATIVE AI ON GENE EDITING MARKET 87
5.9 TECHNOLOGY ANALYSIS 89
5.9.1 KEY TECHNOLOGIES 89
5.9.1.1 Next-generation sequencing 89
5.9.1.2 Electroporation 89
5.9.1.3 Microinjection 89
5.9.2 COMPLEMENTARY TECHNOLOGIES 90
5.9.2.1 Synthetic biology 90
5.9.2.2 Data analysis 90
5.9.2.3 High-throughput screening 91
5.9.3 ADJACENT TECHNOLOGIES 91
5.9.3.1 Single-cell analysis 91
5.9.3.2 Optogenetics 92
5.9.3.3 Gene delivery systems 92
5.10 PATENT ANALYSIS 92
5.11 KEY CONFERENCES AND EVENTS, 2024−2025 94
5.12 REGULATORY ANALYSIS 95
5.12.1 REGULATORY LANDSCAPE 95
5.12.1.1 North America 96
5.12.1.1.1 US 96
5.12.1.1.2 Canada 96
5.12.1.2 Europe 97
5.12.1.2.1 UK 97
 
5.12.1.3 Asia Pacific 98
5.12.1.3.1 China 98
5.12.1.3.2 Japan 98
5.12.1.3.3 South Korea 98
5.12.1.3.4 Australia 99
5.12.1.3.5 Rest of Asia Pacific 99
5.12.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 100
5.13 PORTER’S FIVE FORCES ANALYSIS 102
5.13.1 THREAT OF NEW ENTRANTS 103
5.13.2 THREAT OF SUBSTITUTES 103
5.13.3 BARGAINING POWER OF BUYERS 103
5.13.4 BARGAINING POWER OF SUPPLIERS 103
5.13.5 INTENSITY OF COMPETITIVE RIVALRY 104
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA 104
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 104
5.14.2 KEY BUYING CRITERIA 105
5.15 CASE STUDY ANALYSIS 105
5.15.1 ENHANCED GENE KNOCK-IN EFFICIENCY USING HYBRID SSDNA HDR TEMPLATES IN PRIMARY HUMAN T-CELLS 105
5.15.2 GENE EDITING EFFICIENCY IN CANCER CELL LINES AND T-CELLS USING TRUECUT CAS9 PROTEIN V2 AND TRUEGUIDE SGRNA 106
5.15.3 DEVELOPMENT & SPECIFICITY OPTIMIZATION OF PUREDIT CRISPR CAS9 RNP SYSTEM 106
5.15.4 EVALUATION OF SUREGUIDE CAS9 PROGRAMMABLE NUCLEASE KIT FOR EFFICIENT IN VITRO GENE EDITING 106
5.15.5 GENE EDITING FOR SICKLE-CELL DISEASE USING ZINC FINGER NUCLEASE-MODIFIED HEMATOPOIETIC STEM CELLS 107
5.16 INVESTMENT & FUNDING SCENARIO 107
5.16.1 KEY INVESTMENTS & FUNDING ACTIVITIES, 2021−2024 107
5.17 TRADE DATA ANALYSIS 110
5.17.1 IMPORT DATA, 2019−2023 110
5.17.2 EXPORT DATA, 2019−2023 111
6 GENE EDITING MARKET, BY OFFERING 112
6.1 INTRODUCTION 113
6.2 PRODUCTS 113
6.2.1 EXPANDING APPLICATIONS OF GENE MODIFICATION TECHNIQUES TO
DRIVE MARKET 113
6.3 SERVICES 117
6.3.1 HIGH UPTAKE BY PHARMA COMPANIES FOR DRUG DISCOVERY & DEVELOPMENT TO PROPEL MARKET 117
 
7 GENE EDITING PRODUCTS MARKET, BY TYPE 121
7.1 INTRODUCTION 122
7.2 REAGENTS & CONSUMABLES 122
7.2.1 GENE EDITING KITS 126
7.2.1.1 Increasing demand for mutation & screening kits in
clinical settings to propel market 126
7.2.2 GENE EDITING LIBRARIES 130
7.2.2.1 Genetic screening for cancer research to fuel uptake 130
7.2.3 GENE EDITING REAGENTS 133
7.2.3.1 Ability to create animal models to support market growth 133
7.3 SOFTWARE & SYSTEMS 137
7.3.1 INTEGRATION OF CLOUD-BASED PLATFORMS FOR NGS TO DRIVE MARKET 137
8 GENE EDITING REAGENTS & CONSUMABLES MARKET, BY TECHNIQUE 141
8.1 INTRODUCTION 142
8.2 KNOCK-OUT 142
8.2.1 MODIFICATION OF CRISPR-CAS9 AND TALENS TO PROPEL MARKET 142
8.3 KNOCK-IN 146
8.3.1 UTILIZATION OF DONOR DNA TEMPLATES AND HDR PATHWAYS TO
DRIVE MARKET 146
8.4 GENE SILENCING 149
8.4.1 ADVANCEMENTS IN RNAI TECHNOLOGY AND ANTISENSE THERAPY TO SUPPORT MARKET GROWTH 149
8.5 OTHER TECHNIQUES 153
9 GENE EDITING PRODUCTS MARKET, BY TECHNOLOGY 156
9.1 INTRODUCTION 157
9.2 CRISPR 157
9.2.1 ADVANCEMENTS IN CAS9 PROTEINS TO FUEL UPTAKE 157
9.3 TALENS 161
9.3.1 INCREASING DEMAND FOR THERAPEUTIC DEVELOPMENT TO DRIVE MARKET 161
9.4 ZFN 164
9.4.1 PROVISION OF CUSTOMIZED DESIGN AND TARGETED EDITS TO
BOOST DEMAND 164
9.5 BASE EDITING 167
9.5.1 GROWING APPLICATIONS IN FUNCTIONAL GENOMICS TO FUEL MARKET 167
9.6 ANTISENSE 171
9.6.1 INNOVATIONS IN OLIGONUCLEOTIDE THERAPIES TO SUPPORT MARKET GROWTH 171
9.7 RNAI 174
9.7.1 WIDE APPLICATIONS IN DRUG DISCOVERY TO FUEL UPTAKE 174
9.8 OTHER TECHNOLOGIES 177
10 GENE EDITING PRODUCTS MARKET, BY APPLICATION 180
10.1 INTRODUCTION 181
10.2 CELL LINE ENGINEERING 181
10.2.1 ABILITY TO PROVIDE PRECISE GENE MODIFICATIONS FOR VALIDATION
TO DRIVE MARKET 181
10.3 GENOME EDITING 185
10.3.1 GROWING APPLICATIONS IN BIOTECHNOLOGY TO BOOST DEMAND 185
10.4 DRUG DISCOVERY & DEVELOPMENT 188
10.4.1 UPTAKE OF CRISPR-BASED SYSTEMS FOR DISEASE PROFILING TO
DRIVE MARKET 188
10.5 OTHER APPLICATIONS 192
11 GENE EDITING PRODUCTS MARKET, BY END USER 195
11.1 INTRODUCTION 196
11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 196
11.2.1 INCREASING PRODUCT APPROVALS AND ROBUST CLINICAL
PIPELINE TO PROPEL MARKET 196
11.3 ACADEMIC & RESEARCH INSTITUTES 200
11.3.1 FAVORABLE FUNDING FOR GENOMIC PROJECTS TO DRIVE MARKET 200
11.4 CROS & CDMOS 203
11.4.1 PROVISION OF SPECIALIZED EXPERTISE FOR CLINICAL TRIALS TO
DRIVE MARKET 203
11.5 OTHER END USERS 206
12 GENE EDITING SERVICES MARKET, BY TYPE 210
12.1 INTRODUCTION 211
12.2 CELL LINE DEVELOPMENT & ENGINEERING 211
12.2.1 GROWING DEMAND FOR BIOLOGICS AND BIOSIMILARS TO DRIVE MARKET 211
12.3 GRNA SYNTHESIS & VECTOR CONSTRUCTION 215
12.3.1 ADVANCEMENTS IN GENE EDITING TECHNOLOGIES AND DEMAND FOR PRECISE TARGETING TO DRIVE MARKET 215
12.4 LIBRARY CONSTRUCTION & SCREENING 218
12.4.1 INCREASING FOCUS ON HIGH-THROUGHPUT SCREENING TO PROPEL MARKET 218
12.5 OTHER SERVICES 222
12.5.1 OTHER SERVICES INCLUDE OFF-TARGET ANALYSIS AND MUTAGENESIS SERVICES. 222
13 GENE EDITING SERVICES MARKET, BY APPLICATION 226
13.1 INTRODUCTION 227
13.2 CELL LINE ENGINEERING 227
13.2.1 HIGH UPTAKE IN R&D FOR THERAPEUTIC BIOPRODUCTION TO DRIVE MARKET 227
13.3 GENOME EDITING 231
13.3.1 GROWING FOCUS ON SYNTHETIC GENOMICS TO BOOST DEMAND 231
13.4 DRUG DISCOVERY & DEVELOPMENT 234
13.4.1 GROWING DEMAND FOR PHARMACEUTICAL DEVELOPMENT TO FUEL UPTAKE 234
13.5 OTHER APPLICATIONS 238
14 GENE EDITING SERVICES MARKET, BY END USER 242
14.1 INTRODUCTION 243
14.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 243
14.2.1 GROWING DEMAND FOR ADVANCED MODALITIES TO DRIVE MARKET 243
14.3 ACADEMIC & RESEARCH INSTITUTES 247
14.3.1 INCREASING FUNDING FOR GENOMIC PROJECTS TO PROPEL MARKET 247
14.4 OTHER END USERS 250
15 GENE EDITING MARKET, BY REGION 254
15.1 INTRODUCTION 255
15.2 NORTH AMERICA 256
15.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 261
15.2.2 US 262
15.2.2.1 Growing investments by government authorities and private players to drive market 262
15.2.3 CANADA 266
15.2.3.1 Rise in research & development initiatives for genomics and biotechnology to augment growth 266
15.3 EUROPE 271
15.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 276
15.3.2 GERMANY 278
15.3.2.1 Growing focus on promoting innovations in biotechnology sector to boost market 278
15.3.3 FRANCE 283
15.3.3.1 Ongoing clinical trials and advanced genomic research to
promote growth 283
15.3.4 UK 287
15.3.4.1 Growing focus on developing cell and gene therapy infrastructure to fuel market 287
15.3.5 ITALY 292
15.3.5.1 Increasing availability of research funds to expedite growth 292
15.3.6 SPAIN 296
15.3.6.1 Booming biotechnology sector to contribute to market growth 296
15.3.7 REST OF EUROPE 301
15.4 ASIA PACIFIC 306
15.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 311
15.4.2 CHINA 312
15.4.2.1 Increasing affordability of sequencing platforms and procedures to favor growth 312
 
15.4.3 JAPAN 316
15.4.3.1 Growing focus on cancer research to fuel market 316
15.4.4 INDIA 321
15.4.4.1 Increased awareness about therapeutic benefits of genome engineering to encourage growth 321
15.4.5 SOUTH KOREA 326
15.4.5.1 Rising inclination toward in vivo gene editing to stimulate growth 326
15.4.6 AUSTRALIA 330
15.4.6.1 Favorable regulatory landscape to sustain growth 330
15.4.7 REST OF ASIA PACIFIC 335
15.5 LATIN AMERICA 339
15.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 344
15.5.2 BRAZIL 345
15.5.2.1 Supportive regulatory framework for biotechnology innovation to fuel market 345
15.5.3 REST OF LATIN AMERICA 349
15.6 MIDDLE EAST 353
15.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST 354
15.6.2 GCC COUNTRIES 359
15.6.2.1 Kingdom of Saudi Arabia 364
15.6.2.1.1 Increasing establishment of biotech startups to
support market growth 364
15.6.2.2 United Arab Emirates (UAE) 368
15.6.2.2.1 Growing collaborations for genome sequencing to
drive market 368
15.6.2.3 Other GCC Countries 373
15.6.3 REST OF MIDDLE EAST 377
15.7 AFRICA 382
15.7.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH 382
15.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 386
16 COMPETITIVE LANDSCAPE 388
16.1 INTRODUCTION 388
16.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2021−2024 388
16.3 REVENUE ANALYSIS, 2019−2023 392
16.4 MARKET SHARE ANALYSIS, 2023 394
16.4.1 RANKING OF KEY MARKET PLAYERS 395
16.5 COMPANY VALUATION AND FINANCIAL METRICS 396
16.5.1 COMPANY VALUATION 396
16.5.2 FINANCIAL METRICS 396
16.6 BRAND/PRODUCT COMPARISON 397
16.6.1 THERMO FISHER SCIENTIFIC INC. (US) 397
16.6.2 MERCK KGAA (GERMANY) 397
16.6.3 GENSCRIPT (US) 398
16.6.4 AGILENT TECHNOLOGIES, INC. (US) 398
16.6.5 REVVITY, INC. (US) 398
16.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 398
16.7.1 STARS 398
16.7.2 EMERGING LEADERS 398
16.7.3 PERVASIVE PLAYERS 398
16.7.4 PARTICIPANTS 399
16.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 400
16.7.5.1 Company footprint 400
16.7.5.2 Product footprint 401
16.7.5.3 Service footprint 402
16.7.5.4 Technology footprint 403
16.7.5.5 Region footprint 405
16.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 406
16.8.1 PROGRESSIVE COMPANIES 406
16.8.2 RESPONSIVE COMPANIES 406
16.8.3 DYNAMIC COMPANIES 406
16.8.4 STARTING BLOCKS 406
16.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 408
16.8.5.1 Detailed list of key startups/SMEs 408
16.8.5.2 Competitive benchmarking of key startups/SMEs 409
16.9 COMPETITIVE SCENARIO 409
16.9.1 PRODUCT/SERVICE LAUNCHES & APPROVALS 410
16.9.2 DEALS 411
16.9.3 EXPANSIONS 413
17 COMPANY PROFILES 414
17.1 KEY PLAYERS 414
17.1.1 THERMO FISHER SCIENTIFIC INC. 414
17.1.1.1 Business overview 414
17.1.1.2 Products/Services offered 415
17.1.1.3 Recent developments 417
17.1.1.3.1 Product/Service launches & approvals 417
17.1.1.3.2 Deals 417
17.1.1.3.3 Expansions 418
17.1.1.4 MnM view 418
17.1.1.4.1 Key strengths 418
17.1.1.4.2 Strategic choices 418
17.1.1.4.3 Weaknesses & competitive threats 418
 
17.1.2 MERCK KGAA 419
17.1.2.1 Business overview 419
17.1.2.2 Products/Services offered 420
17.1.2.3 Recent developments 422
17.1.2.3.1 Deals 422
17.1.2.4 MnM view 422
17.1.2.4.1 Key strengths 422
17.1.2.4.2 Strategic choices 422
17.1.2.4.3 Weaknesses & competitive threats 423
17.1.3 GENSCRIPT 424
17.1.3.1 Business overview 424
17.1.3.2 Products/Services offered 425
17.1.3.3 Recent developments 427
17.1.3.3.1 Product/Service launches & approvals 427
17.1.3.3.2 Deals 428
17.1.3.3.3 Expansions 428
17.1.3.4 MnM view 428
17.1.3.4.1 Key strengths 428
17.1.3.4.2 Strategic choices 429
17.1.3.4.3 Weaknesses and competitive threats 429
17.1.4 AGILENT TECHNOLOGIES, INC. 430
17.1.4.1 Business overview 430
17.1.4.2 Products/Services offered 431
17.1.4.3 Recent developments 433
17.1.4.3.1 Deals 433
17.1.4.3.2 Expansions 434
17.1.4.4 MnM view 434
17.1.4.4.1 Key strengths 434
17.1.4.4.2 Strategic choices 434
17.1.4.4.3 Weaknesses & competitive threats 434
17.1.5 REVVITY, INC. 435
17.1.5.1 Business overview 435
17.1.5.2 Products/Services offered 436
17.1.5.3 Recent developments 439
17.1.5.3.1 Product/Service launches 439
17.1.5.3.2 Deals 439
17.1.5.4 MnM view 440
17.1.5.4.1 Key strengths 440
17.1.5.4.2 Strategic choices 440
17.1.5.4.3 Weakness & competitive threats 440
 
17.1.6 LONZA 441
17.1.6.1 Business overview 441
17.1.6.2 Products/Services offered 442
17.1.6.3 Recent developments 443
17.1.6.3.1 Product/Service launches 443
17.1.7 TECAN TRADING AG 444
17.1.7.1 Business overview 444
17.1.7.2 Products/Services offered 445
17.1.7.3 Recent developments 446
17.1.7.3.1 Deals 446
17.1.8 SANGAMO THERAPEUTICS 447
17.1.8.1 Business overview 447
17.1.8.2 Products/Services offered 448
17.1.8.3 Recent developments 448
17.1.8.3.1 Deals 448
17.1.9 PRECISION BIOSCIENCES 449
17.1.9.1 Business overview 449
17.1.9.2 Products/Services offered 450
17.1.9.3 Recent developments 450
17.1.9.3.1 Deals 450
17.1.10 CELLECTIS S.A. 451
17.1.10.1 Business overview 451
17.1.10.2 Products/Services offered 452
17.1.10.3 Recent developments 452
17.1.10.3.1 Deals 452
17.1.11 REGENERON PHARMACEUTICALS, INC. 453
17.1.11.1 Business overview 453
17.1.11.2 Products/Services offered 454
17.1.11.3 Recent developments 454
17.1.11.3.1 Deals 454
17.1.12 AMSBIO 455
17.1.12.1 Business overview 455
17.1.12.2 Products/Services offered 455
17.1.13 CREATIVE BIOGENE 457
17.1.13.1 Business overview 457
17.1.13.2 Products/Services offered 457
17.1.14 SYNTHEGO 460
17.1.14.1 Business overview 460
17.1.14.2 Products/Services offered 460
 
17.1.14.3 Recent developments 462
17.1.14.3.1 Product/Service launches 462
17.1.14.3.2 Deals 462
17.1.14.3.3 Expansions 462
17.1.15 TAKARA BIO INC. 463
17.1.15.1 Business overview 463
17.1.15.2 Products/Services offered 464
17.1.15.3 Recent developments 466
17.1.15.3.1 Deals 466
17.1.15.3.2 Expansions 466
17.1.16 BIO-TECHNE 467
17.1.16.1 Business overview 467
17.1.16.2 Products/Services offered 468
17.1.16.3 Recent developments 470
17.1.16.3.1 Deals 470
17.1.16.3.2 Expansions 470
17.1.17 CARIBOU BIOSCIENCES, INC. 471
17.1.17.1 Business overview 471
17.1.17.2 Products/Services offered 472
17.1.17.3 Recent developments 472
17.1.17.3.1 Deals 472
17.1.18 BIONEER CORPORATION 473
17.1.18.1 Business overview 473
17.1.18.2 Products/Services offered 474
17.1.19 REPROCELL INC. 475
17.1.19.1 Business overview 475
17.1.19.2 Products/Services offered 476
17.2 OTHER PLAYERS 477
17.2.1 ALSTEM INC. 477
17.2.2 NEW ENGLAND BIOLABS 478
17.2.3 INSCRIPTA, INC. 479
17.2.4 BIOCAT GMBH. 480
17.2.5 INTEGRATED DNA TECHNOLOGIES, INC. 481
17.2.6 COBO TECHNOLOGIES APS 482
17.2.7 GENECOPOEIA, INC. 483
17.2.8 HERA BIOLABS 484
17.2.9 STEMCELL TECHNOLOGIES. 485
17.2.10 AXOL BIOSCIENCE LTD. 486
17.2.11 CELLECTA, INC. 487
17.2.12 APPLIED STEMCELL 488
 
18 APPENDIX 489
18.1 DISCUSSION GUIDE 489
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 494
18.3 CUSTOMIZATION OPTIONS 496
18.4 RELATED REPORTS 496
18.5 AUTHOR DETAILS 497